Skip to content
WorldBrand.AI

Capsida Biotherapeutics

Corporate brand

UnclaimedRequest correction

Capsida Biotherapeutics is developing next generation, targeted genetic medicines for rare and more common neurological and ocular diseases across all ages.

Last updated September 1, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Capsida Biotherapeutics is developing next generation, targeted genetic medicines for rare and more common neurological and ocular diseases across all ages. The company's founding technology originated in the lab of Caltech's Viviana Gradinaru, Ph.D. Founded in 2019, Capsida is financed by Versant Ventures and Westlake Village BioPartners and has entered into strategic collaborations with AbbVie, CRISPR Therapeutics, and Lilly's Gene Therapy Division.

History

Capsida Biotherapeutics is developing next generation, targeted genetic medicines for rare and more common neurological and ocular diseases across all ages. The company's founding technology originated in the lab of Caltech's Viviana Gradinaru, Ph.D. Founded in 2019, Capsida is financed by Versant Ventures and Westlake Village BioPartners and has entered into strategic collaborations with AbbVie, CRISPR Therapeutics, and Lilly's Gene Therapy Division.

Recent events

  • Unconfirmed

    Capsida Biotherapeutics secures $140 million in capital[4]

    Capsida Biotherapeutics emerged from stealth mode with $140 million in startup capital, including a $50 million Series A commitment from Versant Ventures and Westlake Village BioPartners and $90 million in upfront and equity investment capital from its collaboration agreement with AbbVie.

  • Capsida announces $50 million Series A financing[5]

    Reported:

    Capsida announced a $50 million Series A financing from Versant Ventures and Westlake Village BioPartners.

  • Capsida and AbbVie announce gene therapy collaboration[6]

    Reported:

    Capsida announced a multi-year strategic collaboration and option agreement with AbbVie to develop targeted gene therapies for three central nervous system disease targets. The agreement includes $80 million in upfront cash and a $10 million equity investment for Capsida.

  • Capsida debuts with $50 million Series A commitment[6]

    Reported:

    Capsida Biotherapeutics announced its emergence from stealth mode with a $50 million Series A commitment from Versant Ventures and Westlake Village BioPartners.

Sources6 sources

  1. 1Capsida Biotherapeutics - Engineering novel AAVs and developing the next generation of gene therapiescapsida.com
  2. 2About - Capsida Biotherapeuticscapsida.com
  3. 3Capsida Biotherapeutics (United States)wikidata.org
  4. 4Capsida Biotherapeutics获得1.4亿美元资金jdsupra.com
  5. 5Capsida宣布获得5000万美元A轮融资medcitynews.com
  6. 6Capsida与AbbVie宣布基因疗法合作prnewswire.com

Cite this profile: Cite the canonical profile. /brand-wiki/capsida-biotherapeutics · Editorial policy · How profiles are compiled